Qure (NASDAQ:QURE – Get Free Report) shares gapped down before the market opened on Friday . The stock had previously closed at $18.05, but opened at $17.55. uniQure shares last traded at $17.73, with ...

The approval keeps uniQure in pole position over its closest rival in the haemophilia B gene therapy race, Pfizer/Roche, whose fidanacogene elaparvovec candidate is in the BENEGENE-2 trial, due to ...

Shares in gene therapy developer uniQure have risen more than 75% after the company reported that Huntington’s disease candidate AMT-130 slowed down the progression of the disorder over two years.

uniQure’s share price has more than doubled following positive interim data from two Phase I/II studies investigating its gene therapy for Huntington’s disease. In patients in the high-dose ...

Pick the best stocks and maximize your portfolio: Sami Corwin has given his Buy rating due to a combination of factors surrounding uniQure’s progress with its AMT-130 gene therapy for Huntington ...

The U.S. Food and Drug Administration will allow uniQure NV to seek accelerated approval for its Huntington’s disease gene therapy, more than doubling the company’s share price on Tuesday.

This regulatory clarity enhances confidence in uniQure’s ability to prioritize and advance their lead gene therapy while managing other developmental programs. Additionally, the recent positive ...

AMT-162 is under development for the treatment of amyotrophic lateral sclerosis. It comprises of Adeno-associated virus rh 10 (AAVrh10) encoding an artificial microRNA (miRNA) that targets SOD1 and ...

Shares of the international gene therapy developer uniQure (NASDAQ: QURE) have been soaring. Investors are responding to positive news regarding the Food and Drug Administration (FDA) and the ...

Shares of uniQure surged on Dec. 10 after the company gave investors great news regarding AMT-130, an experimental gene therapy it's developing to treat Huntington's disease.